Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017
A look at the financing, M&A and alliance activity July–September 2017
Executive Summary
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
You may also be interested in...
US FDA Implements 'Firm-Based' Regulatory Approach To DTC Genetic Health Risk Tests
Formalizing an approach applied to oversight of 23AndMe's direct-to-consumer genetic health risk tests, US FDA Nov. 6 said it plans to allow DTC testing services to be exempted from pre-market review after each individual maker of such an offering comes to the agency for a one-time review to ensure it meets FDA requirements.
Teva Offloads Women's Health Business To Two Firms For $1.38Bn
The generic drug maker signed two deals to divest its women's health business, one with the equity investment firm CVC Capital Partners and the other with Foundation Consumer Healthcare.
Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm
Teva’s planned divestment of non-core assets in order to refocus the company after a troubled first-half has started with a contraceptive device.